Glenmark share price today

Glenmark Pharmaceuticals Ltd's share price was ₹2,504.70 at the close on 4 November 2026. It has been rising for 73 weeks. That is 13.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,812 and ₹2,515, and at that close it sat 99% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Glenmark Pharmaceuticals Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row.

Over the last 11 years the share price moved +240% while the NIFTY 500 moved +257%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 10 quarters in a row, indian funds and insurers (DIIs) cut their stake for 3 quarters in a row and foreign funds (FIIs) raised their stake for 3 quarters in a row.

1. Revenue up on a year earlier for 10 quarters in a row

   In the June 2026 quarter revenue was ₹4,018 crore, +23.1% on a year earlier.

2. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row

   From 20.1% to 17.6% of the company by the September 2026 quarter.

3. Foreign funds (FIIs) raised their stake for 3 quarters in a row

   From 19.2% to 21.5% of the company by the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Glenmark reported revenue of ₹4,018 crore, up 23.1% from ₹3,264 crore a year earlier, and a profit of ₹483 crore, up 927.7% from ₹47.0 crore.

Glenmark results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Glenmark's management discussed these results on a call held on 3 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Glenmark closed at ₹2,504.70 on 4 November 2026, up 38.3% from ₹1,811.50 a year earlier (7 November 2025) and up 378.5% over five years. Its highest weekly close since February 2016 was ₹2,515.00 on 28 August 2026.

Glenmark share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

565 weekly closes from 26 February 2016 to 4 November 2026.

4 Nov 2026: Glenmark closed at ₹2,504.70, up 9.0% on the week and up 7.5% on the month. 31 Aug 2026: ex-date for a dividend of ₹2.50 a share.

Earlier

• 3 Aug 2026: Glenmark held its results call for April to June 2026. Management guided: India formulations are expected to grow 12.0% to 15.0% consistently; the typical mix is 6.0% to 7.0% volume, 3.0% new products and 3.0% to 4.0% value.
• Results for April to June 2026: Revenue up 23.1% and profit up 927.7% on a year earlier.

Glenmark paid ₹2.50 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.10% at the ₹2,504.70 close on 4 November 2026. The last was a dividend of ₹2.50 a share, ex-date 31 August 2026.

Glenmark dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Glenmark Pharmaceuticals Ltd paid out 10% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years. One of those years shows a negative figure because profit itself was negative.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 3 August 2026, Glenmark's management guided: India formulations are expected to grow 12.0% to 15.0% consistently; the typical mix is 6.0% to 7.0% volume, 3.0% new products and 3.0% to 4.0% value.

“For ISB 2301, we will clearly wait until we at least obtain some clinical data in humans and achieve some proof of concept before we even start looking at potential partnerships.”Glenn Saldanha, Chairman & Managing Director, on the call for April to June 2026

What management guided

• Europe is expected to deliver high-single-digit growth in FY27 and return to double-digit growth next year; branded products are planned at about 60.0% of sales within 5 years from around 30.0% today. Ryaltris is expected in 10 markets, including Brazil in H2 FY27, with 2-3 additional European respiratory launches over 12-18 months.
• At least 2 of 3 pending respiratory products, including Fluticasone 110 mcg and Ipratropium, are expected to receive approval in H2 FY27; Fluticasone 44 mcg is expected to provide a full-quarter contribution in July to September 2026.
• Overall R&D spend is expected to remain around 7.0% to 8.0%.
• Aumolertinib commercial launch is anticipated in H2 FY27, first Trastuzumab deruxtecan MA applications in July to September 2026 and Kinayo's first commercial launch in FY28; Aumolertinib, Trastuzumab deruxtecan and Envafolimab are estimated to contribute 500-600 million over 5-6 years.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 3 August 2026.

What is changing at Glenmark, from the latest results and calls: balance sheet transformation, zero gross debt, ryaltris multi-market scaling — $100m to $200-250m by fy28 and abbvie isb 2001, beat platform validated as deal-capable technology.

• Balance Sheet Transformation, Zero Gross Debt. IBD 2001 deal ($700M upfront) eliminated ₹1,300 crore debt; net cash positive from March 2026, interest savings ₹130-150 Cr/year flow directly to profit from FY27. ⚠ estimate
• Ryaltris Multi-Market Scaling — $100M to $200-250M by FY28. Ryaltris $100M FY26 revenue in 55 markets; direct US commercialization April 2026; 8-10 new markets including Brazil; 30-40% growth planned, from management. ⚠ estimate
• AbbVie ISB 2001, BEAT Platform Validated as Deal-Capable Technology. AbbVie licensed ISB 2001 for $700M upfront + $1.225B milestones + double-digit royalties, first external confirmation of IGI's multi-specific BEAT platform applicability at top-5 pharma standards. ⚠ estimate
• India Formulations Outperformance, 13.5% vs IPM 9% FY26. FY26 India formulations grew 13.5% vs IPM 9%; January to March 2026 ₹10,201 million (+8.2% on a year earlier); rank 2 dermatology, rank 3 respiratory; Glyptik (Semaglutide) launched for diabetes turnaround. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the latest results, written 31 May 2026.

April to June 2026 concall reduces operating margin guidance to 21-22% from prior 23%, the 5th guidance revision in 4 concalls, each compounding the credibility discount on future guidance.

The main risks

• Operating profit Margin Guidance Downgrade, 5th Instance: April to June 2026 concall reduces operating margin guidance to 21-22% from prior 23%, the 5th guidance revision in 4 concalls, each compounding the credibility discount on future guidance. ✓ fact
• Ryaltris US Direct Commercialization Execution Risk: April 2026 transition from Menarini to internal US commercialization, building US salesforce from scratch; near-term setup costs compress April to June 2026 margins; success is unproven. ✓ fact
• India Diabetes Franchise Structural Headwind: Generic Dapagliflozin and Sitagliptin pressure existing diabetes brands; January to March 2026 India +8.2% (lowest in 4 quarters); management positioning Glyptik as the offset from April to June 2026. ✓ fact

Our read after the latest results, written 31 May 2026.

When Glenmark reports July to September 2026, these are the 3 checks that show whether the story is still on course. First: US respiratory approvals and launch conversion to show through as planned in the second half.

Glenmark is on 3 of our India lists: Momentum stocks, Small & mid cap stocks and Pharma stocks.

Glenmark Pharmaceuticals Ltd earned ₹483 Cr of net profit in the Jun 2026 quarter, +927.7% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY26 profit was ₹1,362 Cr. Over 10 years profit has grown 6.2% a year on average. That is 12.0% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹47.0 Cr. 3 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was ₹1,362 Cr (+30.1% on the year before).

Why profit moved: revenue changed +23.1% on a year earlier and the margin moved +2.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +2,110.2% and revenue +32.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Glenmark Pharmaceuticals Ltd reported ₹4,018 Cr of revenue in the Jun 2026 quarter, +23.1% on the same quarter a year earlier. That is the 10th quarter in a row with growth on the year before. Over 10 years it has grown 8.4% a year on average. The last full year, FY26, came in at ₹16,983 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹17,737 Cr.

FY26 revenue was ₹16,983 Cr, +27.5% on the year before.

Recent pace: the last four quarters grew +32.5% on average, against 8.4% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +32.9%, against +21.5% a year over the last 8 quarters (accelerating).

Glenmark Pharmaceuticals Ltd's operating margin was 20.0% in the Jun 2026 quarter, 2.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 10.0% and 27.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +2.3 percentage points on the year while gross margin changed +0.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 116% of Glenmark Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹3,445 Cr of operating cash against ₹1,362 Cr of profit. After ₹2,075 Cr of spending on assets, ₹1,370 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 116% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Glenmark Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 83 days in FY26, down from 90 days in FY21. It spent ₹1,853 Cr on assets over the last 3 years. Customers take 107 days to pay, and stock sits for 264 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹16,983 Cr, each day of that cycle ties up about ₹46.5 Cr, so roughly ₹3,862 Cr is tied up in the business at any time.

FY26: customers took 107 days to pay and stock sat for 264 days, about 8.7 months of sales sitting as stock, for a full cycle of 83 days, shorter than FY21's 90.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 264 days. Customers pay about 107 days after that. Suppliers are paid at 288 days. Together that makes the 83-day cycle.

Spending on assets: ₹1,853 Cr over the last 3 years, against ₹1,641 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹909 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Glenmark Pharmaceuticals Ltd's P/E is 22.7×, in the middle of its own history: higher than 69% of past readings. Its usual P/E (the middle reading) is 19.2×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹63.71.